Jul. 3 at 3:41 PM
$LIMN makes bold move into pancreatic cancer diagnostics with new AI-powered consortium. 95% sensitivity/99% specificity on 1,086 subjects looks compelling, but let's not ignore the elephant in the room -
$47K cash reserves. Market potential (
$700M blood diagnostics by 2026) meets financial reality. High-risk, high-reward play.
https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/tm2519876d1_8k.htm